Hydrogen sulfide provides cardioprotection against myocardial/ischemia reperfusion injury in the diabetic state through the activation of the RISK pathway

Medical Gas Research

Volumn 4, Issue 1, 2014, Pages

  Lambert, Jonathan P ^a   Nicholson, Chad K ^a   Amin, Hena ^a   Amin, Sana ^a   Calvert, John W ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardioprotection; Diabetes; Hydrogen sulfide; Myocardial Ischemia reperfusion injury; RISK pathway

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CASPASE 3; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROGEN SULFIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P90; REPERFUSION INJURY SALVAGE KINASE; SODIUM CHLORIDE; SODIUM SULFIDE; TROPONIN I; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLUCOSE BLOOD LEVEL; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HYPERGLYCEMIA; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84924211984     PISSN: None     EISSN: 20459912     Source Type: Journal    
DOI: 10.1186/s13618-014-0020-0     Document Type: Article

References (34)

1. Nathan DM: Long-term complications of diabetes mellitus. N Engl J Med 1993, 328:1676-1685.
2. Zuanetti G, Latini R, Maggioni AP, Santoro L, Franzosi MG: Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol 1993, 22:1788-1794.
3. Rennert G, Saltz-Rennert H, Wanderman K, Weitzman S: Size of acute myocardial infarcts in patients with diabetes mellitus. Am J Cardiol 1985, 55:1629-1630.
4. Jay D, Hitomi H, Griendling KK: Oxidative stress and diabetic cardiovascular complications. Free Radic Biol Med 2006, 40:183-192.
5. Doeller JE, Isbell TS, Benavides G, Koenitzer J, Patel H, Patel RP, Lancaster JR Jr, Darley-Usmar VM, Kraus DW: Polarographic measurement of hydrogen sulfide production and consumption by mammalian tissues. Anal Biochem 2005, 341:40-51.
6. Szabo C: Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 2007, 6:917-935.
7. Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, Tao L, Jiao X, Scalia R, Kiss L, Szabo C, Kimura H, Chow CW, Lefer DJ: Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci U S A 2007, 104:15560-15565.
8. Calvert JW, Elston M, Nicholson CK, Gundewar S, Jha S, Elrod JW, Ramachandran A, Lefer DJ: Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice. Circulation 2010, 122:11-19.
9. Calvert JW, Jha S, Gundewar S, Elrod JW, Ramachandran A, Pattillo CB, Kevil CG, Lefer DJ: Hydrogen sulfide mediates cardioprotection through Nrf2 signaling. Circ Res 2009, 105:365-374.
10. Nicholson CK, Lambert JP, Molkentin JD, Sadoshima J, Calvert JW: Thioredoxin 1 is essential for sodium sulfide-mediated cardioprotection in the setting of heart failure. Arterioscler Thromb Vasc Biol 2013, 33:744-751.
11. Polhemus DJ, Kondo K, Bhushan S, Bir SC, Kevil CG, Murohara T, Lefer DJ, Calvert JW: Hydrogen sulfide attenuates cardiac dysfunction after heart failure via induction of angiogenesis. Circ Heart Fail 2013, 6:1077-1086.
12. Kondo K, Bhushan S, King AL, Prabhu SD, Hamid T, Koenig S, Murohara T, Predmore BL, Gojon G Sr, Gojon G Jr, Wang R, Karusula N, Nicholson CK, Calvert JW, Lefer DJ: H(2)S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase. Circulation 2013, 127:1116-1127.
13. Givvimani S, Munjal C, Gargoum R, Sen U, Tyagi N, Vacek JC, Tyagi SC: Hydrogen sulfide mitigates transition from compensatory hypertrophy to heart failure. J Appl Physiol 2011, 110:1093-1100.
14. Mishra PK, Tyagi N, Sen U, Givvimani S, Tyagi SC: H2S ameliorates oxidative and proteolytic stresses and protects the heart against adverse remodeling in chronic heart failure. Am J Physiol Heart Circ Physiol 2010, 298:H451-H456.
15. Calvert JW, Coetzee WA, Lefer DJ: Novel insights into hydrogen sulfide-mediated cytoprotection. Antioxid Redox Signal 2010, 12:1203-1217.
16. Whiteman M, Gooding KM, Whatmore JL, Ball CI, Mawson D, Skinner K, Tooke JE, Shore AC: Adiposity is a major determinant of plasma levels of the novel vasodilator hydrogen sulphide. Diabetologia 2010, 53:1722-1726.
17. Yusuf M, Kwong Huat BT, Hsu A, Whiteman M, Bhatia M, Moore PK: Streptozotocin-induced diabetes in the rat is associated with enhanced tissue hydrogen sulfide biosynthesis. Biochem Biophys Res Commun 2005, 333:1146-1152.
18. Brancaleone V, Roviezzo F, Vellecco V, De Gruttola L, Bucci M, Cirino G: Biosynthesis of H2S is impaired in non-obese diabetic (NOD) mice. Br J Pharmacol 2008, 155:673-680.
19. Szabo C: Roles of hydrogen sulfide in the pathogenesis of diabetes mellitus and its complications. Antioxid Redox Signal 2012, 17:68-80.
20. Peake BF, Nicholson CK, Lambert JP, Hood RL, Amin H, Amin S, Calvert JW: Hydrogen sulfide preconditions the db/db diabetic mouse heart against ischemia-reperfusion injury by activating Nrf2 signaling in an Erkdependent manner. Am J Physiol Heart Circ Physiol 2013, 304:H1215-H1224.
21. El-Seweidy MM, Sadik NA, Shaker OG: Role of sulfurous mineral water and sodium hydrosulfide as potent inhibitors of fibrosis in the heart of diabetic rats. Arch Biochem Biophys 2011, 506:48-57.
22. Suzuki K, Olah G, Modis K, Coletta C, Kulp G, Gero D, Szoleczky P, Chang T, Zhou Z, Wu L, Wang R, Papapetropoulos A, Szabo C: Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function. Proc Natl Acad Sci U S A 2011, 108:13829-13834.
23. Jain SK, Bull R, Rains JL, Bass PF, Levine SN, Reddy S, McVie R, Bocchini JA: Low levels of hydrogen sulfide in the blood of diabetes patients and streptozotocin-treated rats causes vascular inflammation? Antioxid Redox Signal 2010, 12:1333-1337.
24. Hausenloy DJ, Yellon DM: Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 2007, 12:217-234.
25. Yellon DM, Baxter GF: Reperfusion injury revisited: is there a role for growth factor signaling in limiting lethal reperfusion injury? Trends Cardiovasc Med 1999, 9:245-249.
26. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, Seguchi O, Myoishi M, Minamino T, Ohara T, Nagai Y, Nanot S, Watanabe K, Fukuzawa S, Hirayama A, Nakamura N, Kimura K, Fujii K, Ishihara M, Saito Y, Tomoike H, Kitamura S: Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007, 370:1483-1493.
27. Duchen MR: Roles of mitochondria in health and disease. Diabetes 2004, 53(Suppl 1):S96-S102.
28. Aon MA, Cortassa S, Akar FG, O'Rourke B: Mitochondrial criticality: a new concept at the turning point of life or death. Biochim Biophys Acta 2006, 1762:232-240.
29. Churchill EN, Mochly-Rosen D: The roles of PKCdelta and epsilon isoenzymes in the regulation of myocardial ischaemia/reperfusion injury. Biochem Soc Trans 2007, 35:1040-1042.
30. Davidson SM, Hausenloy D, Duchen MR, Yellon DM: Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol 2006, 38:414-419.
31. Boengler K, Schulz R, Heusch G: Loss of cardioprotection with ageing. Cardiovasc Res 2009, 83:247-261.
32. Meng XB, Sun GB, Wang M, Sun J, Qin M, Sun XB: P90RSK and Nrf2 Activation via MEK1/2-ERK1/2 Pathways Mediated by Notoginsenoside R2 to Prevent 6-Hydroxydopamine-Induced Apoptotic Death in SH-SY5Y Cells. Evid Based Complement Alternat Med 2013, 2013:971712.
33. Ghaboura N, Tamareille S, Ducluzeau PH, Grimaud L, Loufrani L, Croue A, Tourmen Y, Henrion D, Furber A, Prunier F: Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3beta signaling. Basic Res Cardiol 2011, 106:147-162.
34. Li DY, Tao L, Liu H, Christopher TA, Lopez BL, Ma XL: Role of ERK1/2 in the anti-apoptotic and cardioprotective effects of nitric oxide after myocardial ischemia and reperfusion. Apoptosis 2006, 11:923-930.